Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis. [PDF]
Ahmed S+6 more
europepmc +1 more source
Joint Damage Progression in Patients with Rheumatoid Arthritis in Clinical Remission. Do Biologics Perform Better Than Synthetic Antirheumatic Drugs? [PDF]
Elena Ciubotariu, Cem Gabay, Axel Finckh
openalex +1 more source
Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis. [PDF]
Perković D+4 more
europepmc +1 more source
Factors Associated With The Initiation Of Biologic Disease Modifying Antirheumatic Drugs In Texas Medicaid Patients With Rheumatoid Arthritis [PDF]
G. Kim+3 more
openalex +1 more source
Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns. [PDF]
Merola JF+6 more
europepmc +1 more source
Lipid profiles in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs [PDF]
Anna Filipowicz‐Sosnowska+2 more
openalex +1 more source
Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis [PDF]
Shunsuke Mori
openalex +1 more source